Metagenomi, Inc. Reports Q3 2025 Financial Results

Metagenomi, Inc. ( (MGX) ) has released its Q3 earnings. Here is a breakdown of the information Metagenomi, Inc. presented to its investors.

Metagenomi, Inc. is a precision genetic medicines company specializing in developing curative therapeutics using its proprietary genome editing toolbox, operating primarily in the biotechnology sector. The company is headquartered in Emeryville, California. In its latest earnings report for the quarter ended September 30, 2025, Metagenomi, Inc. reported a net loss of $20.4 million, reflecting a slight increase from the $18.8 million loss in the same quarter of the previous year. The company’s revenue from collaborations decreased to $8.7 million from $11.5 million year-over-year, while operating expenses were slightly reduced to $31.5 million from $33.9 million. Despite the financial losses, Metagenomi maintains a strong cash position with $32.8 million in cash and cash equivalents and $151.3 million in marketable securities. The company continues to invest in research and development, with expenses totaling $25.3 million for the quarter. Looking ahead, Metagenomi’s management remains focused on advancing its pipeline of genetic medicine programs and leveraging its genome editing technology to achieve future growth and development milestones.